<div id="readability-page-1">Integra LifeSciences (NASDAQ:IART - Get Free Report) issued its earnings results on Thursday. The life sciences company reported $0.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.04, FiscalAI reports. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 14.06%. The business had revenue of $434.93 million during the quarter, compared to analysts' expectations of $429.62 million. During the same quarter in the prior year, the business posted $0.97 EPS. The company's revenue for the quarter was down 1.7% on a year-over-year basis. Integra LifeSciences updated its Q1 2026 guidance to 0.370-0.450 EPS and its FY 2026 guidance to 2.300-2.400 EPS.<div>Get Integra LifeSciences alerts:</div><ul><li>3 Undervalued Midcaps Ready to Pop</li></ul>Here are the key takeaways from Integra LifeSciences' conference call:<ul> <li>Company guides to modest 2026 growth with revenues of $1.66B–$1.70B, adjusted EPS of $2.30–$2.40, expects operating cash flow to exceed $200M, and plans meaningful deleveraging toward a 2.5x–3.5x leverage target by year-end 2026.</li> <li>Management says it made material progress on quality and supply reliability—establishing a transformation office and a supply-chain control tower—and is on track to bring the Braintree facility online by end of June to enable a planned Q4 relaunch of SurgiMend.</li> <li>Early, accelerated relaunches of PriMatrix and DuraRepair (12 months ahead of plan) had strong customer reception and are expected to contribute to revenue recovery in 2026.</li> <li>Tariff uncertainty remains a near-term risk after the Supreme Court ruling and a proposed new Section 122 tariff; Integra paid ~$20M in tariffs in 2025 and continues to model an approximate $0.32 EPS headwind for 2026 while not assuming any recovery of prior payments.</li> <li>Tissue Technologies underperformed in Q4 (revenues down 12.8%) driven by ongoing MediHoney remediation and a tough Integra Skin comp, and MediHoney revenue is excluded from 2026 guidance.</li> </ul><h2>Integra LifeSciences Price Performance</h2>Shares of IART traded down $0.68 during trading hours on Thursday, reaching $10.91. The company had a trading volume of 420,409 shares, compared to its average volume of 695,915. The company has a current ratio of 3.14, a quick ratio of 1.80 and a debt-to-equity ratio of 1.73. Integra LifeSciences has a 12-month low of $10.60 and a 12-month high of $24.36. The firm has a 50 day simple moving average of $12.02 and a 200-day simple moving average of $13.22. The company has a market capitalization of $849.78 million, a price-to-earnings ratio of -1.69 and a beta of 1.04. <h2>Wall Street Analyst Weigh In</h2>A number of research analysts recently issued reports on IART shares. Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of Integra LifeSciences in a research note on Monday, December 29th. Citigroup decreased their price target on shares of Integra LifeSciences from $12.00 to $11.00 and set a &#34;sell&#34; rating for the company in a research note on Friday, October 31st. Wall Street Zen upgraded shares of Integra LifeSciences from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, November 8th. Truist Financial reiterated a &#34;hold&#34; rating and set a $13.00 target price (down from $15.00) on shares of Integra LifeSciences in a research note on Monday, November 3rd. Finally, JPMorgan Chase &amp; Co. boosted their price target on Integra LifeSciences from $12.00 to $13.00 and gave the company an &#34;underweight&#34; rating in a research report on Friday, October 31st. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of &#34;Reduce&#34; and an average target price of $15.00.Get Our Latest Report on Integra LifeSciences<h2>Institutional Investors Weigh In On Integra LifeSciences</h2>Several institutional investors have recently modified their holdings of the company. Global Retirement Partners LLC purchased a new position in shares of Integra LifeSciences in the fourth quarter valued at $25,000. Osaic Holdings Inc. increased its holdings in Integra LifeSciences by 36.6% during the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company's stock valued at $51,000 after acquiring an additional 1,104 shares in the last quarter. Tower Research Capital LLC TRC raised its position in Integra LifeSciences by 595.6% during the second quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company's stock worth $98,000 after acquiring an additional 6,814 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Integra LifeSciences in the fourth quarter valued at about $124,000. Finally, Amundi grew its position in shares of Integra LifeSciences by 17,193.8% in the second quarter. Amundi now owns 11,068 shares of the life sciences company's stock valued at $150,000 after purchasing an additional 11,004 shares during the last quarter. Hedge funds and other institutional investors own 84.78% of the company's stock. <h2>Key Integra LifeSciences News</h2>Here are the key news stories impacting Integra LifeSciences this week:<ul> <li>Positive Sentiment: Q4 adjusted results beat expectations — adjusted EPS of $0.83 (vs. ~$0.79 consensus) and revenue of $434.9M topped estimates, showing the core business can still generate operating earnings. IART Beats Q4 Estimates (Zacks)</li> <li>Positive Sentiment: Operational actions: management highlighted a simplified operating model and expects $25–$30M of savings in 2026, which should help margins if execution continues. IART Q4 Release (GlobeNewswire)</li> <li>Neutral Sentiment: Full‑year 2026 guidance is roughly in range: revenue guidance ($1.662–$1.702B) implies low‑single‑digit growth and adjusted EPS guidance ($2.30–$2.40) overlaps consensus — this tempers panic but lacks upside surprise. Guidance vs Consensus (Investing.com)</li> <li>Negative Sentiment: Q1 2026 EPS guidance ($0.37–$0.45) and revenue range ($375–$390M) were below Street expectations for the quarter, creating immediate near‑term earnings risk and a catalyst for selling. Q1 Guidance Miss (Investing.com)</li> <li>Negative Sentiment: Large FY2025 non‑cash items remain a concern: a $511M goodwill impairment led to a GAAP net loss and highlights prior overpayments/operational stress — investors may worry about balance sheet and future impairment risk. Impairment &amp; Details (Quiver)</li> <li>Negative Sentiment: Segment weakness and cash metrics: Tissue Technologies revenue fell ~12.8% in Q4 (wound reconstruction down substantially), operating cash flow and free cash flow conversion weakened, and net debt/leverage (net debt ~$1.6B, ~4.5x) leave limited flexibility. Segment &amp; Balance Sheet (GlobeNewswire)</li> </ul><h2>Integra LifeSciences Company Profile</h2> (Get Free Report)Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices. Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.<h2>Featured Stories</h2><ul><li>Five stocks we like better than Integra LifeSciences</li><li>Gold Ran First - but This Cycle May Belong to Silver</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li><li>REVEALED: Something Big Happening Behind White House Doors</li><li>ALERT: Drop these 5 stocks before the market opens tomorrow!</li><li>Elon Musk already made me a “wealthy man”</li></ul><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUFSVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUFSVA"/>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.<h2>Should You Invest $1,000 in Integra LifeSciences Right Now?</h2>Before you consider Integra LifeSciences, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integra LifeSciences wasn't on the list.While Integra LifeSciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here </div>

IART

Integra LifeSciences (NASDAQ:IART) reported quarterly earnings of $0.83 EPS, exceeding expectations of $0.79 by $0.04. Revenue was $434.93 million, surpassing the forecast of $429.62 million, but down 1.7% year-over-year. The company updated its 2026 guidance, projecting EPS of $2.30–$2.40 and revenue of $1.66B–$1.70B. Despite a negative net margin of 30.15%, management noted progress in quality and supply reliability. Shares fell to $10.91, with analysts divided on ratings, reflecting a consensus rating of "Reduce" and an average target price of $15.00.

Integra LifeSciences (NASDAQ:IART) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS